EGFR抑制剂当与PD-1单抗药物组合使用时能够提高免疫疗法在肺腺癌中的疗效

查看全部

马上注册，结交更多好友，享用更多功能，让你轻松玩转社区。

您需要登录才可以下载或查看，没有账号？立即注册

x

版主对下面的信息有研究和解读吗？谢谢

来源：《Science Immunology》
发生区域：日本
发布时间：2020.1.31
摘要：EGFR抑制剂当与PD-1单抗药物组合使用时能够提高免疫疗法在肺腺癌中的疗效。
关键字：EGFR、厄洛替尼、PD-1单抗、肺癌
”
原文：
科学家在一项新的肿瘤微环境中研究肺癌的表皮生长因子EGFR时发现，抗PD-1药物在EGFR突变时通常是效果不佳的。然而，EGFR抑制剂厄洛替尼若与PD-1单抗药物联用的效果要胜过其中任何一种单独治疗方案，将会在肺腺癌的免疫治疗中起到重要作用。

The clinical efficacy of anti–PD-1 (programmed cell death–1) monoclonal antibody (mAb) against cancers with oncogenic driver gene mutations, which often harbor a low tumor mutation burden, is variable, suggesting different contributions of each driver mutation to immune responses. Here, we investigated the immunological phenotypes in the tumor microenvironment (TME) of epidermal growth factor receptor (EGFR)–mutated lung adenocarcinomas, for which anti–PD-1 mAb is largely ineffective. Whereas EGFR-mutated lung adenocarcinomas had a noninflamed TME, CD4+ effector regulatory T cells, which are generally present in the inflamed TME, showed high infiltration. The EGFR signal activated cJun/cJun N-terminal kinase and reduced interferon regulatory factor–1; the former increased CCL22, which recruits CD4+ regulatory T cells, and the latter decreased CXCL10 and CCL5, which induce CD8+ T cell infiltration. The EGFR inhibitor erlotinib decreased CD4+ effector regulatory T cells infiltration in the TME and in combination with anti–PD-1 mAb showed better antitumor effects than either treatment alone. Our results suggest that EGFR inhibitors when used in conjunction with anti–PD-1 mAb could increase the efficacy of immunotherapy in lung adenocarcinomas.

来自苹果APP客户端